Some therapeutic approaches using GLP‐1 analogs and dipeptidyl peptidase IV inhibitors have demonstrated that hyperglycemia in patients with type 2 diabetes is improved by stimulating the action of GLP‐1 (Herman et al., 2006). This evidence concerns the gene GCG and Hyperglycemia.